NLS Pharmaceutics Dirección
Dirección controles de criterios 2/4
NLS Pharmaceutics' CEO is Alex Zwyer, appointed in Aug 2015, has a tenure of 8.75 years. total yearly compensation is $917.00K, comprised of 94.1% salary and 5.9% bonuses, including company stock and options. directly owns 3.03% of the company’s shares, worth $247.21K. The average tenure of the management team and the board of directors is 3.3 years and 1.9 years respectively.
Información clave
Alex Zwyer
Chief Executive Officer (CEO)
US$917.0k
Compensación total
| Porcentaje del salario del CEO | 94.1% |
| Permanencia del CEO | 8.8yrs |
| Participación del CEO | 3.0% |
| Permanencia media de la dirección | 3.3yrs |
| Promedio de permanencia en la Junta Directiva | 1.9yrs |
Actualizaciones recientes de la dirección
Recent updates
NLS Pharmaceutics gets delisting determination letter from Nasdaq
Oct 05NLS Pharma falls 17% despite positive Phase 2 data for narcolepsy candidate
Sep 27NLS Pharma to get Japanese patent related to Quilience for attention, sleep disorders
Jul 28Here's Why We're A Bit Worried About NLS Pharmaceutics' (NASDAQ:NLSP) Cash Burn Situation
Mar 04
Companies Like NLS Pharmaceutics (NASDAQ:NLSP) Could Be Quite Risky
Nov 12Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$917k | US$863k | -US$12m |
| Sep 30 2023 | n/a | n/a | -US$14m |
| Jun 30 2023 | n/a | n/a | -US$15m |
| Mar 31 2023 | n/a | n/a | -US$16m |
| Dec 31 2022 | US$1m | US$977k | -US$16m |
| Sep 30 2022 | n/a | n/a | -US$16m |
| Jun 30 2022 | n/a | n/a | -US$16m |
| Mar 31 2022 | n/a | n/a | -US$14m |
| Dec 31 2021 | US$1m | US$1m | -US$12m |
Compensación vs. Mercado: Alex's total compensation ($USD917.00K) is above average for companies of similar size in the US market ($USD658.06K).
Compensación vs. Ingresos: Alex's compensation has been consistent with company performance over the past year.
CEO
Alex Zwyer (54 yo)
8.8yrs
Permanencia
US$917,000
Compensación
Mr. Alexander Zwyer, also known as Alex, M.B.A., Co-Founded NLS Pharmaceutics AG (formerly known as NLS Pharma AG) in 2015 until 2021 and serves as its Chief Executive Officer and Director since August 201...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 8.8yrs | US$917.00k | 3.03% $ 247.2k | |
| Co-Founder & Chief Scientific Officer | 3.3yrs | US$179.00k | 2.17% $ 177.7k | |
| CFO and Head of Finance & Human Resources | less than a year | US$61.00k | sin datos | |
| Chief Medical Officer and Global Head of Research & Development | 1.7yrs | US$390.00k | 2.75% $ 225.1k | |
| General Counsel | 7yrs | sin datos | sin datos |
3.3yrs
Permanencia media
54yo
Promedio de edad
Equipo directivo experimentado: NLSP's management team is considered experienced (3.3 years average tenure).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 8.8yrs | US$917.00k | 3.03% $ 247.2k | |
| Independent Director | less than a year | sin datos | sin datos | |
| Independent Chairman of the Board | 8.8yrs | US$44.00k | 5.09% $ 416.0k | |
| Independent Director | less than a year | US$152.00k | sin datos | |
| Independent Director | 2.9yrs | US$30.00k | 0.34% $ 28.1k | |
| Independent Director | less than a year | sin datos | sin datos |
1.9yrs
Permanencia media
55yo
Promedio de edad
Junta con experiencia: La junta directiva de NLSP no se considera experimentada (1.8 años de permanencia promedio), lo que sugiere una nueva junta directiva.